Early breast cancer
Conditions
Brief summary
IDFS* of patients four years after surgery overall (*IDFS: time from surgery to whatever comes first a) ipsilateral invasive breast tumor recurrence, b) local/regional invasive breast cancer recurrence, c) distant recurrence, d) death attributable to any cause incl. breast cancer, e) contralateral invasive breast cancer or f) Second primary non-breast invasive cancer)
Detailed description
overall survival (OS), IDFS in each study arm separately, time from surgery to whatever comes first a) distant recurrence, b) death attributable to any cause incl. breast cancer or c) second primary non-breast invasive cancer, Safety including incidence of adverse events
Interventions
DRUGINAVOLISIB
DRUGTrodelvy 200 mg powder for concentrate for solution for infusion
DRUGLynparza 100 mg film-coated tablets
DRUGIpatasertib
DRUGLynparza 150 mg film-coated tablets
DRUGTecentriq 1 200 mg concentrate for solution for infusion
Sponsors
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IDFS* of patients four years after surgery overall (*IDFS: time from surgery to whatever comes first a) ipsilateral invasive breast tumor recurrence, b) local/regional invasive breast cancer recurrence, c) distant recurrence, d) death attributable to any cause incl. breast cancer, e) contralateral invasive breast cancer or f) Second primary non-breast invasive cancer) | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival (OS), IDFS in each study arm separately, time from surgery to whatever comes first a) distant recurrence, b) death attributable to any cause incl. breast cancer or c) second primary non-breast invasive cancer, Safety including incidence of adverse events | — |
Countries
Germany
Outcome results
None listed